NETRF 2023 Annual Report
Jim Rodin’s dedication to the Neuroendocrine Tumor Research Foundation (NETRF) is a testament to his enduring love for his late wife, Sandy, and their shared commitment to leaving a lasting impact on the world.
Their life together was marked by a shared sense of adventure that took them to all corners of the globe. From exploring the historic streets of Europe to immersing themselves in the vibrant cultures of Asia, Jim and Sandy embraced the wonders of travel with open hearts and curious minds.
But their love for adventure extended beyond their own experiences. Jim and Sandy opened their home to international students, welcoming them into their lives as if they were their own children. These students became an integral part of their family, and Jim and Sandy took great joy in witnessing their growth and success over the years. From celebrating academic achievements to attending weddings and even becoming grandparents, the bond between Jim, Sandy, and their “adopted” children was unbreakable.
Their life took an unexpected turn when Sandy was diagnosed with neuroendocrine cancer. Jim stood by Sandy’s side as they navigated the challenges of obtaining an accurate diagnosis and exploring treatment options. Neuroendocrine cancer, as many patients and their families have found, proved to be mysterious and elusive, with symptoms often masquerading as other health ailments, leading to misdiagnosis and delays in appropriate care.
Jim witnessed firsthand the importance of early and accurate detection. Determined to make a difference, Jim turned to the NETRF as a way to honor Sandy’s memory and support research that could improve early detection methods and patient outcomes.
What particularly inspired Jim was the work of NETRF’s early-career investigators. These individuals shared a similar spirit of determination and were driven to explore unique pathways in their quest to find better treatments and, ultimately, a cure for neuroendocrine cancer. Jim recognized the potential of these talented researchers and directed his philanthropy toward sponsoring a NETRF Mentored Research Award in Sandy’s memory.
By providing these dedicated individuals with the means and opportunity to fully dedicate themselves to neuroendocrine cancer research, the NETRF Mentored Research Award not only fosters their professional growth but also enriches the entire NET community. Jim’s unwavering support and dedication to empowering these investigators is a testament to his belief in the power of investing in the next generation of medical pioneers.
“We have to leave this world a better place. By supporting the next generation and investing in research, we can make a profound and lasting impact on those affected by neuroendocrine cancer,” says Jim.
We extend our deepest gratitude to Jim Rodin for his enduring support.